Please refer attached pdf.
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ind-Swift Laboratories reported standalone revenue of Rs 6,357 lakhs for FY2026, up 13% from Rs 5,622 lakhs in FY2025. Standalone profit after tax dropped sharply to Rs 256 lakhs from Rs 2,561 lakhs in the previous year. On a consolidated basis, PAT was negligible at Rs 1.53 lakhs vs Rs 2,505 lakhs in FY2025. The previous year included exceptional income of Rs 2,232 lakhs from land/building sale. Exceptional items for FY2026 were positive at Rs 110 lakhs. Borrowings reduced significantly - standalone non-current borrowings fell to Rs 1,211 lakhs from Rs 2,254 lakhs. The company issued 1.81 crore shares during the year due to warrant conversions and ESOP. Auditors issued unmodified opinion on both standalone and consolidated results.
The stock shows weak profitability despite revenue growth due to absence of exceptional gains that boosted FY2025. The sharp PAT decline from Rs 2,561 lakhs to Rs 256 lakhs on standalone basis indicates operational performance without one-time gains was significantly lower. Reduced debt is a positive balance sheet development.